{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:40:22Z","timestamp":1785404422483,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.humpath.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T07:28:13Z","timestamp":1601018893000},"page":"82-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas"],"prefix":"10.1016","volume":"106","author":[{"given":"Yui","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-2932","authenticated-orcid":false,"given":"Takeshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Jiromaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yasumatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-1182","authenticated-orcid":false,"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.09.004_bib1","series-title":"World Health organization classification of tumours of endocrine Organs","first-page":"81","article-title":"Papillary thyroid carcinoma","author":"Rosai","year":"2017"},{"key":"10.1016\/j.humpath.2020.09.004_bib2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.6004\/jnccn.2018.0089","article-title":"NCCN guidelines insights: thyroid carcinoma, version 2. 2018","volume":"16","author":"Haddad","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.humpath.2020.09.004_bib3","series-title":"World Health organization classification of tumours of endocrine Organs","first-page":"104","article-title":"Anaplastic thyroid carcinoma","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.humpath.2020.09.004_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2010.167","article-title":"Molecular analysis of thyroid tumors","volume":"24","author":"Nikiforov","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrc1836","article-title":"Pathogenetic mechanisms in thyroid follicular-cell neoplasia","volume":"6","author":"Kondo","year":"2006","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.humpath.2020.09.004_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2020.09.004_bib7","first-page":"1093","article-title":"Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications","volume":"6","author":"Rabes","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.humpath.2020.09.004_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2020.09.004_bib9","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1172\/JCI69766","article-title":"Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers","volume":"123","author":"Ricarte-Filho","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humpath.2020.09.004_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.28484","article-title":"ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer","volume":"120","author":"Leeman-Neill","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2020.09.004_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-020-0574-4","article-title":"Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)","author":"Chu","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087170","article-title":"Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas","volume":"9","author":"P\u00e9rot","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.humpath.2020.09.004_bib13","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2020.09.004_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/PAS.0000000000000368","article-title":"A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma","volume":"39","author":"Chou","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1089\/thy.2011.0511","article-title":"Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors","volume":"22","author":"Hamatani","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.humpath.2020.09.004_bib16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/thy.2016.0101","article-title":"ROS1 rearrangement in thyroid cancer","volume":"26","author":"Ritterhouse","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.humpath.2020.09.004_bib17","first-page":"1","article-title":"Response to entrectinib in differentiated thyroid cancer with a ROS1 fusion","volume":"1","author":"Liu","year":"2017","journal-title":"JCO Press Oncol"},{"key":"10.1016\/j.humpath.2020.09.004_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"Gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.humpath.2020.09.004_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.21037\/tlcr.2017.08.02","article-title":"Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer","volume":"6","author":"Farago","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.humpath.2020.09.004_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.09.004_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.humpath.2020.09.004_bib23","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Can Res"},{"key":"10.1016\/j.humpath.2020.09.004_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/his.12399","article-title":"Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH","volume":"65","author":"Hutarew","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.09.004_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/modpathol.2013.192","article-title":"Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers","volume":"27","author":"Yoshida","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/his.14010","article-title":"Diagnostic utility of pan-Trk immunohistochemistry in inflammatory myofibroblastic tumours","volume":"76","author":"Yamamoto","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.09.004_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13981","article-title":"Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2020.09.004_bib29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib30","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2020.09.004_bib31","first-page":"172","article-title":"Clinicopathologic and molecular characteristics of synchronous colorectal carcinoma with mismatch repair deficiency","volume":"42","author":"Nakano","year":"2018","journal-title":"Am J Surg\u00a0Pathol"},{"key":"10.1016\/j.humpath.2020.09.004_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Canc Lett"},{"key":"10.1016\/j.humpath.2020.09.004_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2265.2007.03077.x","article-title":"BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma","volume":"68","author":"Costa","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.humpath.2020.09.004_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1089\/thy.2013.0610","article-title":"Concomitant RAS, RET\/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma","volume":"24","author":"Zou","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.humpath.2020.09.004_bib35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JTO.0000000000000135","article-title":"Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma","volume":"9","author":"Mizukami","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2020.09.004_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.humpath.2020.09.004_bib37","first-page":"37","article-title":"The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer","volume":"1795","author":"Acquaviva","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2020.09.004_bib38","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:37:53Z","timestamp":1758645473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720301775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S0046817720301775"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.004","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}